Tirzepatide Beyond Weight Loss: Sleep Apnea, Diabetes & Heart (2026)

Approved and emerging indications

Sleep apnea: a landmark approval

In SURMOUNT-OSA, tirzepatide sharply cut the apnea-hypopnea index. Among participants not using PAP therapy, it reduced breathing disruptions far more than placebo.

Diabetes and metabolic effects

As Mounjaro, tirzepatide lowers blood sugar substantially (A1c reductions up to roughly 2.5% in the SURPASS program) alongside weight loss, and it improves several cardiometabolic markers such as blood pressure and lipids. Whether that translates into fewer heart attacks and strokes is what the SURPASS-CVOT outcomes trial is designed to answer.

Mounjaro vs Zepbound: same molecule, different brands

A common source of confusion: Mounjaro and Zepbound are the same drug (tirzepatide) sold under different names for different approved uses. Mounjaro carries the type 2 diabetes indication; Zepbound carries the weight-management and sleep-apnea indications. The brand split matters for insurance, since coverage often keys to the indication and the specific product prescribed.

Coverage and off-label realities

Insurance coverage varies widely and continues to evolve, especially for obesity and sleep apnea. A clinician can prescribe either brand off-label, but plans frequently decline off-label use, which can make out-of-pocket costs substantial. Emerging areas like cardiovascular protection and liver disease may broaden the picture over time, but until trials read out and the FDA acts, those remain investigational for tirzepatide.

What this means for patients

The right brand and indication depend on your diagnosis: Mounjaro for diabetes, Zepbound for weight or sleep apnea. Off-label use is possible but coverage is limited, and compounded tirzepatide is not FDA-approved for any indication. For the weight-loss data, see weight loss by dose.

What is coming next

Tirzepatide’s story is still being written. Beyond the ongoing cardiovascular-outcomes trial, researchers are studying it in heart failure with preserved ejection fraction, chronic kidney disease, and metabolic liver disease, and next-generation molecules such as triple agonists are advancing through trials. For patients, the practical implication is that the label may broaden over the next few years, potentially improving insurance coverage for specific conditions. Until those approvals arrive, though, prescribing for unapproved uses remains off-label, and coverage for it is typically limited. The safest approach is to match today’s approved indication to your diagnosis and revisit options as the evidence base grows.

Frequently asked questions

What is tirzepatide approved for?

FDA-approved as Mounjaro for type 2 diabetes (2022) and as Zepbound for chronic weight management (2023) and moderate-to-severe obstructive sleep apnea with obesity (2024).

Is tirzepatide approved for heart disease?

Not as a standalone cardiovascular indication as of 2026. The SURPASS-CVOT outcomes trial is studying that question.

Does tirzepatide help sleep apnea?

Yes — in SURMOUNT-OSA it substantially reduced breathing disruptions, leading to the first-ever FDA drug approval for obstructive sleep apnea in December 2024.

Are Mounjaro and Zepbound the same drug?

Yes. Both are tirzepatide, sold under different brand names for different approved indications.